466 related articles for article (PubMed ID: 27671969)
1. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol.
Arnold JD; Sarkodie EP; Coleman ME; Goldstein DA
J Sex Med; 2016 Nov; 13(11):1773-1777. PubMed ID: 27671969
[TBL] [Abstract][Full Text] [Related]
2. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
[TBL] [Abstract][Full Text] [Related]
3. Risk for Venous Thromboembolism in Transgender Patients Undergoing Cross-Sex Hormone Treatment: A Systematic Review.
Kotamarti VS; Greige N; Heiman AJ; Patel A; Ricci JA
J Sex Med; 2021 Jul; 18(7):1280-1291. PubMed ID: 34140253
[TBL] [Abstract][Full Text] [Related]
4. Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review.
Boskey ER; Taghinia AH; Ganor O
JAMA Surg; 2019 Feb; 154(2):159-169. PubMed ID: 30516808
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
[TBL] [Abstract][Full Text] [Related]
6. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
Toorians AW; Thomassen MC; Zweegman S; Magdeleyns EJ; Tans G; Gooren LJ; Rosing J
J Clin Endocrinol Metab; 2003 Dec; 88(12):5723-9. PubMed ID: 14671159
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
Seaman HE; de Vries CS; Farmer RD
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):427-36. PubMed ID: 15269926
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review.
Streed CG; Harfouch O; Marvel F; Blumenthal RS; Martin SS; Mukherjee M
Ann Intern Med; 2017 Aug; 167(4):256-267. PubMed ID: 28738421
[TBL] [Abstract][Full Text] [Related]
9. Effect of Cross-Sex Hormone Therapy on Venous Thromboembolism Risk in Male-to-Female Gender-Affirming Surgery.
Haveles CS; Wang MM; Arjun A; Zaila KE; Lee JC
Ann Plast Surg; 2021 Jan; 86(1):109-114. PubMed ID: 32079810
[TBL] [Abstract][Full Text] [Related]
10. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
11. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.
Spitzer WO
J Obstet Gynaecol Can; 2003 Dec; 25(12):1011-8. PubMed ID: 14663535
[TBL] [Abstract][Full Text] [Related]
12. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P
Menopause; 2018 Nov; 25(11):1297-1305. PubMed ID: 30358726
[TBL] [Abstract][Full Text] [Related]
13. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
Dinger J; Bardenheuer K; Heinemann K
Climacteric; 2016 Aug; 19(4):349-56. PubMed ID: 27174159
[TBL] [Abstract][Full Text] [Related]
14. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
[TBL] [Abstract][Full Text] [Related]
15. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
[TBL] [Abstract][Full Text] [Related]
16. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF
Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345
[TBL] [Abstract][Full Text] [Related]
17. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment.
Nota NM; Wiepjes CM; de Blok CJM; Gooren LJG; Peerdeman SM; Kreukels BPC; den Heijer M
Brain; 2018 Jul; 141(7):2047-2054. PubMed ID: 29688280
[TBL] [Abstract][Full Text] [Related]
18. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V
J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590
[TBL] [Abstract][Full Text] [Related]
19. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study.
Getahun D; Nash R; Flanders WD; Baird TC; Becerra-Culqui TA; Cromwell L; Hunkeler E; Lash TL; Millman A; Quinn VP; Robinson B; Roblin D; Silverberg MJ; Safer J; Slovis J; Tangpricha V; Goodman M
Ann Intern Med; 2018 Aug; 169(4):205-213. PubMed ID: 29987313
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
